Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 7 | 2023 | 339 | 2.570 |
Why?
|
| Premature Birth | 3 | 2023 | 138 | 1.620 |
Why?
|
| Biosensing Techniques | 2 | 2022 | 3 | 1.510 |
Why?
|
| MicroRNAs | 2 | 2022 | 17 | 1.500 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 43 | 1.350 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 22 | 1.330 |
Why?
|
| Life Style | 3 | 2021 | 342 | 1.300 |
Why?
|
| Blood Glucose | 4 | 2022 | 346 | 1.110 |
Why?
|
| Pregnancy | 15 | 2024 | 1516 | 1.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 760 | 1.020 |
Why?
|
| Ethnic Groups | 2 | 2019 | 501 | 0.980 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2024 | 2 | 0.950 |
Why?
|
| Signal Transduction | 2 | 2021 | 30 | 0.890 |
Why?
|
| Humans | 30 | 2024 | 18430 | 0.880 |
Why?
|
| Pediatric Obesity | 2 | 2024 | 80 | 0.860 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.860 |
Why?
|
| Female | 25 | 2024 | 13136 | 0.830 |
Why?
|
| Prenatal Care | 2 | 2021 | 134 | 0.820 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 34 | 0.820 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 530 | 0.770 |
Why?
|
| Preconception Care | 1 | 2021 | 48 | 0.760 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 2 | 0.710 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 2 | 0.710 |
Why?
|
| NF-kappa B | 1 | 2020 | 11 | 0.710 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 5 | 0.710 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2020 | 1 | 0.710 |
Why?
|
| Eicosanoids | 1 | 2020 | 1 | 0.710 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 1 | 0.710 |
Why?
|
| Reperfusion Injury | 1 | 2020 | 2 | 0.710 |
Why?
|
| Thinness | 1 | 2020 | 29 | 0.710 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2020 | 10 | 0.700 |
Why?
|
| Olmesartan Medoxomil | 1 | 2019 | 1 | 0.700 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 10 | 0.700 |
Why?
|
| Phospholipids | 1 | 2019 | 3 | 0.690 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 3 | 0.690 |
Why?
|
| Nutritional Status | 1 | 2019 | 30 | 0.690 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 11 | 0.680 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 28 | 0.680 |
Why?
|
| Prospective Studies | 6 | 2021 | 1314 | 0.680 |
Why?
|
| Platinum | 1 | 2019 | 1 | 0.680 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 1 | 0.680 |
Why?
|
| Immobilized Nucleic Acids | 1 | 2019 | 1 | 0.680 |
Why?
|
| DNA Probes | 1 | 2019 | 2 | 0.680 |
Why?
|
| Adult | 15 | 2024 | 7910 | 0.670 |
Why?
|
| Cardiovascular System | 1 | 2018 | 4 | 0.650 |
Why?
|
| Healthy Aging | 1 | 2018 | 8 | 0.640 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 724 | 0.630 |
Why?
|
| Health Status Disparities | 1 | 2019 | 153 | 0.610 |
Why?
|
| Fetal Macrosomia | 1 | 2017 | 27 | 0.580 |
Why?
|
| Male | 15 | 2024 | 10440 | 0.550 |
Why?
|
| Animals | 4 | 2020 | 261 | 0.520 |
Why?
|
| Cohort Studies | 6 | 2024 | 2672 | 0.520 |
Why?
|
| Attitude to Health | 1 | 2017 | 177 | 0.520 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 233 | 0.470 |
Why?
|
| Young Adult | 6 | 2021 | 2518 | 0.430 |
Why?
|
| Self Report | 2 | 2018 | 256 | 0.410 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2024 | 159 | 0.400 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2022 | 2 | 0.380 |
Why?
|
| Electrochemical Techniques | 2 | 2022 | 2 | 0.380 |
Why?
|
| Limit of Detection | 2 | 2022 | 2 | 0.380 |
Why?
|
| Case-Control Studies | 3 | 2023 | 1173 | 0.350 |
Why?
|
| Mice | 2 | 2020 | 68 | 0.350 |
Why?
|
| Creatinine | 2 | 2020 | 65 | 0.340 |
Why?
|
| Communication | 2 | 2020 | 202 | 0.320 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 214 | 0.310 |
Why?
|
| Risk Factors | 4 | 2023 | 3449 | 0.300 |
Why?
|
| Self Care | 1 | 2018 | 175 | 0.290 |
Why?
|
| Patient Participation | 1 | 2018 | 144 | 0.290 |
Why?
|
| Aged | 6 | 2022 | 6417 | 0.290 |
Why?
|
| Body Mass Index | 3 | 2020 | 974 | 0.280 |
Why?
|
| Child | 5 | 2024 | 2571 | 0.270 |
Why?
|
| Prevalence | 3 | 2020 | 911 | 0.270 |
Why?
|
| Obesity | 2 | 2018 | 855 | 0.270 |
Why?
|
| Middle Aged | 7 | 2021 | 8284 | 0.270 |
Why?
|
| Medical Informatics | 1 | 2016 | 45 | 0.270 |
Why?
|
| Infant, Newborn | 3 | 2024 | 872 | 0.270 |
Why?
|
| Bayes Theorem | 2 | 2023 | 69 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 392 | 0.260 |
Why?
|
| Urban Population | 1 | 2016 | 124 | 0.260 |
Why?
|
| Poverty | 1 | 2016 | 182 | 0.250 |
Why?
|
| Child, Preschool | 4 | 2024 | 1478 | 0.250 |
Why?
|
| Organophosphates | 1 | 2024 | 9 | 0.250 |
Why?
|
| Flame Retardants | 1 | 2024 | 11 | 0.240 |
Why?
|
| United States | 3 | 2024 | 4164 | 0.240 |
Why?
|
| Child Development | 1 | 2024 | 52 | 0.230 |
Why?
|
| Cesarean Section | 1 | 2024 | 30 | 0.230 |
Why?
|
| Maternal Exposure | 1 | 2024 | 60 | 0.230 |
Why?
|
| Hispanic Americans | 1 | 2016 | 428 | 0.230 |
Why?
|
| Pregnancy Outcome | 2 | 2023 | 159 | 0.230 |
Why?
|
| Fluorocarbons | 1 | 2023 | 12 | 0.220 |
Why?
|
| Eclampsia | 1 | 2023 | 12 | 0.220 |
Why?
|
| Adolescent | 3 | 2021 | 3798 | 0.220 |
Why?
|
| African Americans | 1 | 2016 | 490 | 0.220 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.220 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 38 | 0.210 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 3 | 0.210 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 23 | 0.210 |
Why?
|
| Endonucleases | 1 | 2022 | 3 | 0.210 |
Why?
|
| DNA | 1 | 2022 | 25 | 0.210 |
Why?
|
| Phenols | 1 | 2022 | 34 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2018 | 747 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 8 | 0.200 |
Why?
|
| Rats | 2 | 2020 | 29 | 0.200 |
Why?
|
| Autistic Disorder | 1 | 2023 | 105 | 0.200 |
Why?
|
| Kidney | 2 | 2020 | 54 | 0.200 |
Why?
|
| Glycolysis | 1 | 2021 | 1 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 3 | 0.190 |
Why?
|
| Up-Regulation | 1 | 2021 | 7 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 15 | 0.190 |
Why?
|
| Hypoxia | 1 | 2021 | 8 | 0.190 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 399 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 55 | 0.190 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 164 | 0.180 |
Why?
|
| Apoptosis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Pandemics | 4 | 2023 | 292 | 0.180 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 19 | 0.180 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 8 | 0.180 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 3 | 0.170 |
Why?
|
| Albuminuria | 1 | 2019 | 41 | 0.170 |
Why?
|
| Inverted Repeat Sequences | 1 | 2019 | 1 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 2 | 0.170 |
Why?
|
| Calibration | 1 | 2019 | 8 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 127 | 0.170 |
Why?
|
| Feedback | 1 | 2019 | 22 | 0.170 |
Why?
|
| Qualitative Research | 2 | 2021 | 272 | 0.170 |
Why?
|
| Gestational Age | 1 | 2019 | 119 | 0.170 |
Why?
|
| Consumer Behavior | 1 | 2019 | 30 | 0.160 |
Why?
|
| Minority Groups | 1 | 2019 | 105 | 0.160 |
Why?
|
| Text Messaging | 1 | 2019 | 31 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2019 | 53 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2019 | 129 | 0.160 |
Why?
|
| Disease Progression | 1 | 2019 | 271 | 0.160 |
Why?
|
| Biomarkers | 1 | 2019 | 308 | 0.160 |
Why?
|
| Insulin | 1 | 2019 | 208 | 0.160 |
Why?
|
| Motivation | 1 | 2019 | 137 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2018 | 29 | 0.150 |
Why?
|
| Oral Health | 1 | 2018 | 21 | 0.150 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 444 | 0.150 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 60 | 0.150 |
Why?
|
| Maternal Behavior | 1 | 2017 | 13 | 0.150 |
Why?
|
| Overweight | 1 | 2019 | 276 | 0.140 |
Why?
|
| Heart Failure | 1 | 2022 | 398 | 0.140 |
Why?
|
| Social Environment | 1 | 2017 | 90 | 0.140 |
Why?
|
| Weight Gain | 1 | 2018 | 181 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 226 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2019 | 1143 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 1245 | 0.120 |
Why?
|
| Depression | 3 | 2023 | 518 | 0.110 |
Why?
|
| Nephritis, Interstitial | 1 | 2012 | 2 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
| Lipocalins | 1 | 2012 | 2 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1360 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 36 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2018 | 848 | 0.100 |
Why?
|
| Anxiety | 2 | 2022 | 156 | 0.090 |
Why?
|
| Disclosure | 1 | 2021 | 19 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2022 | 147 | 0.090 |
Why?
|
| Focus Groups | 1 | 2021 | 154 | 0.090 |
Why?
|
| Age of Onset | 1 | 2020 | 82 | 0.090 |
Why?
|
| Patient Portals | 1 | 2020 | 25 | 0.090 |
Why?
|
| Metformin | 1 | 2020 | 61 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2020 | 119 | 0.080 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 15 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 197 | 0.080 |
Why?
|
| Registries | 1 | 2020 | 490 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2018 | 93 | 0.070 |
Why?
|
| Chicago | 1 | 2016 | 27 | 0.070 |
Why?
|
| Health Resources | 1 | 2016 | 38 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 267 | 0.060 |
Why?
|
| Esters | 1 | 2024 | 5 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2024 | 59 | 0.060 |
Why?
|
| Comorbidity | 1 | 2016 | 619 | 0.060 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 45 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2016 | 256 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2023 | 34 | 0.060 |
Why?
|
| California | 1 | 2020 | 2365 | 0.060 |
Why?
|
| Stillbirth | 1 | 2023 | 30 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 19 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 371 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 50 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 82 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2022 | 98 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 1389 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 93 | 0.050 |
Why?
|
| Hypertension | 1 | 2016 | 524 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 9 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2021 | 20 | 0.050 |
Why?
|
| Glucose | 1 | 2021 | 30 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 168 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2022 | 468 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 624 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 244 | 0.040 |
Why?
|
| North Carolina | 1 | 2018 | 34 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 96 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 114 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 106 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 247 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 321 | 0.030 |
Why?
|
| Medicaid | 1 | 2018 | 211 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 193 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 321 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Fibrosis | 1 | 2012 | 7 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 28 | 0.030 |
Why?
|
Concepts
(207)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->